As Byetta stalls, Lilly reveals Plan B-WEB ONLY
Ever wonder why acquisition-minded CEO John Lechleiter has been cool to the idea of Eli Lilly and Co. buying Amylin Pharmaceuticals Inc., Lilly’s partner on the diabetes medicine Byetta? One reason might be that Lilly is developing its own entrant into the promising new class of GLP-1 diabetes drugs, which was pioneered by the 2005 […]